ArticleClinical and experimental medicine2025
PDCD1 as a targetable immune checkpoint hub: therapeutic insights for ibrutinib-resistant CLL management.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow, specifically involving the overproduction of abnormal lymphocytes. Using two independent datasets (GSE249956 and GSE98206), differentially expressed genes (DEGs) were identified between ibrutinib-resistant and sensitive CLL samples. Protein-protein interaction (PPI) network analysis revealed key hub genes related to resistance. Three common hub genes were shared across datasets: PDCD1, CD1C, and ITGB2. PDCD1, encoding the immune checkpoint protein PD-1, was selected for deeper investigation due to its important role in immune regulation and relevance in drug resistance. Post-transcriptional regulation of PDCD1 was explored by the construction of competing endogenous RNA (ceRNA) networks linking lncRNAs and miRNAs that may modulate PDCD1 expression, indicating complex upstream regulatory mechanisms. Transcription factors potentially regulating PDCD1 were identified, suggesting layers of transcriptional control contributing to ibrutinib resistance. Drug-gene interaction analysis showed that although PDCD1 is not directly targeted by ibrutinib. This implicates immune checkpoint blockade as a promising therapeutic strategy to overcome or complement resistance in CLL. In the broader context, PD-1 expression in CLL cells is linked to active proliferation and immune escape. Overall, our findings emphasize PDCD1's central role in ibrutinib resistance through immune checkpoint pathways and support the rationale for combining BTK inhibitors with immune checkpoint blockade therapies in resistant CLL cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.